Replimune Group Inc Cash Flow Conversion Efficiency
Replimune Group Inc cash flow conversion efficiency. Based on the latest financial reports, Replimune Group Inc (REPL) has a cash flow conversion efficiency ratio of -0.313x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.95 Million) by net assets ($210.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Replimune Group Inc (2017–2025)
Cash flow conversion efficiency of Replimune Group Inc from 2017 to 2025. This chart illustrates how Replimune Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Replimune Group Inc (REPL) stock price for real-time trading data and today's change.
Replimune Group Inc Cash Flow Conversion Ratio Explained
Replimune Group Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Replimune Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Replimune Group Inc ranked by their cash flow conversion efficiency. Also see how much is Replimune Group Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Huitong Energy Co Ltd
SHG:600605
|
-0.034x |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
0.063x |
|
GCM Grosvenor Inc
NASDAQ:GCMG
|
0.311x |
|
Hextar Global Bhd
KLSE:5151
|
0.095x |
|
Argo Properties NV
TA:ARGO
|
0.019x |
|
PHARMING GRP SP. ADRS
F:PHG
|
0.039x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Arena REIT
AU:ARF
|
0.027x |
Annual Cash Flow Conversion Efficiency for Replimune Group Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Replimune Group Inc from 2017 to 2025. Review REPL financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $415.84 Million | $-192.25 Million | -0.462x | +6.65% |
| 2024-03-31 | $374.51 Million | $-185.47 Million | -0.495x | -114.76% |
| 2023-03-31 | $555.29 Million | $-128.05 Million | -0.231x | -15.39% |
| 2022-03-31 | $411.23 Million | $-82.18 Million | -0.200x | -62.35% |
| 2021-03-31 | $498.73 Million | $-61.39 Million | -0.123x | +62.65% |
| 2020-03-31 | $183.72 Million | $-60.55 Million | -0.330x | -79.04% |
| 2019-03-31 | $137.86 Million | $-25.38 Million | -0.184x | -132.27% |
| 2018-03-31 | $-28.07 Million | $-16.01 Million | 0.571x | -7.17% |
| 2017-03-31 | $-11.52 Million | $-7.08 Million | 0.615x | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more